Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial (Q93158347)

From Wikidata

Jump to navigation Jump to search

scientific article published on 12 November 2018

Language	Label	Description	Also known as
English	Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial	scientific article published on 12 November 2018

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

phase III clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Alberto Garaventa

22

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

24

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Maria Rita Castellani

object named as

Maria Rita Castellani

20

1 reference

ORCID Public Data File 2021

Ulrike Pötschger

2

object named as

Ulrike Pötschger

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Maja Beck Popovic

15

object named as

Maja Beck Popovic

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

author name string

Ruth Ladenstein

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Dominique Valteau-Couanet

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Roberto Luksch

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Victoria Castel

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Isaac Yaniv

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Genevieve Laureys

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Penelope Brock

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Jean Marie Michon

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Cormac Owens

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Godfrey Chi Fung Chan

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Ellen Ruud

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Henrik Schroeder

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Guenter Schreier

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Hans Loibner

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Keith Holmes

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Mark N Gaze

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Andrew D J Pearson

23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

publication date

12 November 2018

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

1617-1629

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5--a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Neuroblastoma: developmental biology, cancer genomics and immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients: a SIOPEN Phase 1 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose finding study for the use of subcutaneous recombinant interleukin-2 to augment natural killer cell numbers in an outpatient setting for stage 4 neuroblastoma after megatherapy and autologous stem-cell reinfusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A multilocus technique for risk evaluation of patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pseudo-observations in survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy implications of the role of interleukin-2 in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Getting the glycosylation right: implications for the biotechnology industry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Immunomodulatory effects of myeloid-derived suppressor cells in diseases: Role in cancer and infections

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2818%2930578-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(18)30578-3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30442501%20AND%20SRC:MED&resulttype=core&format=json

4 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q93158347&oldid=1953083216"